Medicare adds penicillin allergy testing to preventive care for seniors
H.R. 5736 — PAVE Act · Filed by H. Griffith (R-VA) · 9 cosponsors · Introduced Oct 10, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill adds penicillin allergy verification and evaluation to Medicare's covered preventive services for seniors, requiring doctors to identify patients with reported penicillin allergies, assess whether the allergy is real, provide information about the health risks of false allergy labels, and refer patients to allergy specialists when appropriate. The bill is based on evidence that over 90% of patients labeled with penicillin allergies can safely take the drug, and that false labels lead to worse health outcomes and higher costs.
Why we flagged it
The bill expands Medicare's preventive services to include a clinical assessment that corrects a widespread diagnostic error, improving patient outcomes and reducing unnecessary antibiotic resistance. This is straightforward public-health policy, not a market intervention or regulatory carve-out.
What the text implies
- Penicillin allergy 'delabeling' may increase penicillin prescribing, potentially affecting antibiotic resistance patterns and the market share of alternative antibiotics (cephalosporins, fluoroquinolones) among seniors.
- The bill's allowance for separate payment for 'structured penicillin allergy validation and evaluation services' on the same day as preventive visits may create a new billable service category, generating revenue for allergy/immunology specialists and diagnostic labs.
The full analysis lists 3 implications of this text.
Who stands to gain
allergy and immunology specialists; diagnostic laboratories (allergy testing); penicillin and beta-lactam antibiotic manufacturers